巩膜外敷贴近距离放射治疗用于视网膜母细胞瘤
该单中心回顾性研究纳入11只眼的11个视网膜母细胞瘤,采用碘-125或钌-106巩膜外敷贴近距离放射治疗,平均顶点剂量44 Gy。5年无复发生存率80%、眼球生存率80%、总生存率100%;D组肿瘤可能是局部复发的危险因素。
要点
- 巩膜外敷贴近距离放射治疗可作为选择性B组和C组视网膜母细胞瘤的主要或次要治疗。
- D组晚期肿瘤可能是局部复发的危险因素。
- 应预期放射性视网膜病变等具有视觉意义的并发症。
核心结论
- 巩膜外敷贴近距离放射治疗是选择性视网膜母细胞瘤眼(B组和C组)的有效主要或次要治疗方式。
- 晚期D组肿瘤可能是局部复发的危险因素。
- 应预期放射性视网膜病变等具有视觉意义的并发症。
研究设计与样本
- 单中心视网膜母细胞瘤病例的回顾性综述。
- 采用Kaplan-Meier法分析生存结局。
主要发现
- 11只眼的11个肿瘤接受碘-125或钌-106巩膜外敷贴近距离放射治疗,平均顶点剂量44 Gy。
- 肿瘤分组为B组5只眼(46%)、C组3只眼(27%)、D组3只眼(27%)。
- 平均随访75.4个月,最终视力优于20/200者占70%,眼球保留9只眼(82%)。
- 局部复发率为18%,平均复发时间为巩膜外敷贴近距离放射治疗后17.4个月;2个D组肿瘤在二次巩膜外敷贴近距离放射治疗后复发并接受眼球摘除。
- 放射性视网膜病变平均发生时间为巩膜外敷贴近距离放射治疗后17.4个月;未记录到转移或致死事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: To report visual outcomes, survival outcomes and complications following episcleral brachytherapy (EB) for retinoblastoma. METHODS: Retrospective review of retinoblastoma cases treated with EB in a single institution. Survival outcomes were analysed using the Kaplan-Meier method. RESULTS: Eleven tumours of 11 eyes were treated with either iodine-125 or ruthenium-106 EB with a mean apical dose of 44 Gy. The tumours were classified as group B in 5 (46%), C in 3 (27%) or D in 3 (27%) eyes, respectively. Mean follow-up time was 75.4 months. EB served as primary treatment in 3 eyes (27%) and secondary treatment in 8 eyes (73%). Final visual acuity was better than 20/200 in 70% of cases. Globe preservation was achieved in 9 (82%) eyes. Local recurrence occurred in 18% of cases at a mean onset of 17.4 months after EB. Two group D tumours that recurred after secondary EB underwent enucleation. Mean onset of radiation retinopathy was 17.4 months following EB. No metastatic or fatal events were recorded. Kaplan-Meier analysis showed recurrence-free survival and ocular survival of 80% and overall survival of 100% at 5 years after EB. CONCLUSION: EB is an effective primary or secondary treatment modality for selected retinoblastoma eyes (groups B and C). Advanced group D tumours may represent a risk factor for local recurrence. Visually significant complications such as radiation retinopathy should be anticipated.
引用
- Echegaray JJ, Al-Zahrani YA, Singh A, et al. Episcleral brachytherapy for retinoblastoma. Br J Ophthalmol. 2019. PMID: 31122912. doi:10.1136/bjophthalmol-2019-313985
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。